Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Zhang, Li ^a   Wu, Guoqin ^a   Gao, Di ^a   Liu, Guijian ^a   Pan, Lin ^a   Ni, Liyan ^b   Li, Zheng ^a   Wang, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b Laboratory of Shanghai Skin Diseases Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYTOKINE; JO 1 ANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTHRITIS; ARTICLE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DYSPHAGIA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; MASS SCREENING; NEOPLASM; OBSERVATIONAL STUDY; POLYMYOSITIS; RAYNAUD PHENOMENON; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; COMPLICATION; DEMOGRAPHY; FEMALE; MALE; META ANALYSIS; PUBLISHING;

DEMOGRAPHY; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; POLYMYOSITIS; PUBLICATION BIAS; RISK FACTORS;

EID: 84969513497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155381     Document Type: Article

References (53)

1. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, et al. (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93: 318-332.
2. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63: 3439-3447. doi: 10.1002/art.30513 PMID: 21702020
3. Hallowell RW, Ascherman DP, Danoff SK (2014) Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med 35: 239-248. doi: 10.1055/s-0034-1371528 PMID: 24668538
4. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138: 1464-1474. doi: 10.1378/chest.10-0180 PMID: 21138882
5. Feng Y, Ni L, Wang Q (2013) Administration of cathepsin B inhibitor CA-074Me reduces inflammation and apoptosis in polymyositis. J Dermatol Sci 72: 158-167. doi: 10.1016/j.jdermsci.2013.06.014 PMID: 23890703
6. Reed AM, Ernste F (2009) The inflammatory milieu in idiopathic inflammatory myositis. Curr Rheumatol Rep 11: 295-301. PMID: 19691933
7. Zhang L, Fu XH, Yu Y, Shui RH, Li C, Zeng HY, et al. (2015) Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis. Lab Invest 95: 65-77. doi: 10.1038/labinvest.2014.135 PMID: 25384123
8. Sauty A, Rochat T, Schoch OD, Hamacher J, Kurt AM, Dayer JM, et al. (1997) Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 10: 2907-2912. PMID: 9493684
9. Mimori T, Nakashima R, Hosono Y (2012) Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 14: 264-274. doi: 10.1007/s11926-012-0246-6 PMID: 22367479
10. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54: 597-613. PMID: 16546580
11. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136: 1341-1347. doi: 10.1378/chest.08-2740 PMID: 19581351
12. Targoff IN (1993) Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 100: 116S-123S. PMID: 8423380
13. Cen X, Zuo C, Yang M, Yin G, Xie Q (2013) A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy. Clin Dev Immunol 2013: 648570. doi: 10.1155/2013/648570 PMID: 24106519
14. Chen YJ, Wu CY, Shen JL (2007) Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 87: 33-38. PMID: 17225013
15. Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, et al. (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47: 614-622. PMID: 12522835
16. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347. PMID: 1090839
17. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403-407. PMID: 1089199
18. American Thoracic S, European Respiratory S (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304. PMID: 11790668
19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. PMID: 3802833
20. Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. (2005) Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44: 1282-1286.
21. Chua F, Higton AM, Colebatch AN, O'Reilly K, Grubnic S, Vlahos I, et al. (2012) Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 51: 1870-1876.
22. Wu H, Geng D, Xu J (2013) An approach to the development of interstitial lung disease in dermatomyositis: a study of 230 cases in China. J Int Med Res 41: 493-501. doi: 10.1177/0300060513476435 PMID: 23569020
23. Chen IJ, Jan Wu YJ, Lin CW, Fan KW, Luo SF, Ho HH, et al. (2009) Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 28: 639-646. doi: 10.1007/s10067-009-1110-6 PMID: 19247576
24. Won Huh J, Soon Kim D, Keun Lee C, Yoo B, Bum Seo J, Kitaichi M, et al. (2007) Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med 101: 1761-1769. PMID: 17428649
25. Ji SY, Zeng FQ, Guo Q, Tan GZ, Tang HF, Luo YJ, et al. (2010) Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl) 123: 517-522.
26. Ishigaki K, Maruyama J, Hagino N, Murota A, Takizawa Y, Nakashima R, et al. (2013) Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis. Rheumatol Int 33: 2381-2389. doi: 10.1007/s00296-013-2735-y PMID: 23553518
27. Fathi M, Barbasso Helmers S, Lundberg IE (2012) KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 271: 589-597. doi: 10.1111/j.1365-2796.2011.02459.x PMID: 21950266
28. Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53: 2196-2203.
29. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. (2009) Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 60: 2183-2192. doi: 10.1002/art.24631 PMID: 19565490
30. Muro Y, Sugiura K, Akiyama M (2013) Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol 32: 395-398. doi: 10.1007/s10067-012-2142-x PMID: 23250474
31. Sun Y, Liu Y, Yan B, Shi G (2013) Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int 33: 1295-1302. doi: 10.1007/s00296-012-2545-7 PMID: 23143553
32. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a metaanalysis. Arthritis Care Res (Hoboken) 65: 1316-1324.
33. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51: 1278-1284.
34. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440.
35. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49: 1726-1733.
36. Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. (2013) Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 65: 1307-1315.
37. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014: 290797. doi: 10.1155/2014/290797 PMID: 24741583
38. Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee EB, et al. (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11: 223. doi: 10.1186/1471-2474-11-223 PMID: 20875136
39. Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, et al. (2015) Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol.
40. Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. (2008) Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 59: 677-685. doi: 10.1002/art.23571 PMID: 18438901
41. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, et al. (2013) The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 107: 745-752. doi: 10.1016/j.rmed.2013.01.014 PMID: 23485097
42. Fischer A, du Bois R (2012) Interstitial lung disease in connective tissue disorders. Lancet 380: 689-698. doi: 10.1016/S0140-6736(12)61079-4 PMID: 22901890
43. Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. (2014) Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9: e98824. doi: 10.1371/journal.pone.0098824 PMID: 24905449
44. Vij R, Strek ME (2013) Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143: 814-824. doi: 10.1378/chest.12-0741 PMID: 23460159
45. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G (2004) Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 83: 35-42.
46. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. (2012) Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 11: 739-745. doi: 10.1016/j.autrev.2012.01.006 PMID: 22326685
47. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. (2007) A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 56: 3112-3124. PMID: 17763410
48. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28: 2230-2237. PMID: 11669162
49. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576. PMID: 15880816
50. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum 60: 2193-2200. doi: 10.1002/art.24621 PMID: 19565506
51. Miller FW, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, et al. (2013) Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum 65: 3239-3247. doi: 10.1002/art.38137 PMID: 23983088
52. Chinoy H, Adimulam S, Marriage F, New P, Vincze M, Zilahi E, et al. (2012) Interaction of HLA- DRB1∗03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis 71: 961-965. doi: 10.1136/annrheumdis-2011-200182 PMID: 22186711
53. Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Wendy T, et al. (2006) In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 8: R13. PMID: 16507114